Navigation Links
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
Date:11/12/2007

IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), presented today results from the Company's two Phase III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD (once- daily) formulation, a new formulation of ISTA's ocular, non-steroidal anti- inflammatory agent. The multi-center studies evaluated the new once-daily formulation of Xibrom versus placebo in over 500 patients who underwent cataract surgery. The highly statistically significant findings demonstrated Xibrom QD (once-daily) was superior to placebo (P less than or equal to 0.0001) in achieving both the primary efficacy endpoint of absence of ocular inflammation 15 days following surgery and the secondary efficacy endpoint of elimination of ocular pain at day one. In addition, compared to placebo, bromfenac produced a lower overall incidence of ocular adverse events. William B. Trattler, M.D. presented the results during the 2007 Annual Meeting of the American Academy of Ophthalmology (AAO) being held in New Orleans, Louisiana.

ISTA also announced today a second poster presentation at the AAO meeting. This study demonstrated the currently marketed twice-daily formulation of Xibrom was as effective as both diclofenac sodium 0.1% ophthalmic solution or ketorolac tromethamine 0.5% ophthalmic solution, each dosed four times daily, when used for 3 months in the treatment of cystoid macular edema (CME) following uncomplicated cataract surgery.

Poster Presentations at AAO Meeting:

Monday, November 12th; 12pm - 2pm, Location: Morial Convention Center, Hall D

Abstract # 0259: Integrated Results from 2 Phase III Clinical Trials of a Once Daily Bromfenac Ophthalmic Solution for Ocular S
'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email: